---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-104032"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:12:18.049662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KalVista Q1 net loss $40.4M; FDA accepts NDA for sebetralstat, PDUFA June 17, 2025

## Summary
- Net loss $40.4M ($0.87/share) vs $25.3M prior year; no revenue recognized.
- Cash and securities $174.3M at July 31, down from $210.4M on April 30.
- FDA accepted NDA for oral sebetralstat for HAE; PDUFA goal date June 17, 2025.
- EMA validated MAA submission for sebetralstat; UK/Japan filings planned later in 2024.
- Phase 3 KONFIDENT-KID pediatric trial initiated dosing with oral disintegrating tablet.

## SEC filing metadata
- accession: 0000950170-24-104032
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017024104032/0000950170-24-104032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017024104032/kalv-20240905.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-104032
- JSON: https://secwatch.observer/filing/0000950170-24-104032.json
- Plain text: https://secwatch.observer/filing/0000950170-24-104032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.